Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

NCT07652294 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

645

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis
Inflammatory Bowel Diseases
Colitis
Colitis, Ulcerative

Interventions

DRUG: SPY001
DRUG: SPY002
DRUG: SPY003

Sponsor

Spyre Therapeutics, Inc.